about
Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancerComprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYCErythropoietin drives breast cancer progression by activation of its receptor EPORCharacterisation of genome-wide PLZF/RARA target genes.Differential display as an approach to study differentiation and differentiation therapy in AML.Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.Hoxa6 potentiates short-term hemopoietic cell proliferation and extended self-renewal.Methods for the molecular analysis of cancer. An overview.Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblastsRepurposing medicinal compounds for blood cancer treatment.Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia.QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics.A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies.GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936.Immunotherapy of myeloid leukaemia.Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblastsAn international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase.Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia.Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.Low-dose salinomycin induces anti-leukemic responses in AML and MLL.Gene expression profiling in MDS and AML: potential and future avenues.Living long and ageing well: is epigenomics the missing link between nature and nurture?Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1.Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.Detecting DNA methylation using the methylated CpG island amplification and microarray technique.Microarray for epigenetic changes: gene expression arrays.Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism.Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.Assessment of the cellular response to the induced expression of defensin sense and antisense cDNA in acute promyelocytic leukemia cell lines.Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.The relationship between the location of the breakpoint within the M-bcr and clinical parameters.
P50
Q28346582-36355FC6-C33A-42EF-93E8-003BBD288F69Q33560429-43E04427-37C6-4030-B35E-B611028C9651Q33888764-F1BD3A5C-2A95-4860-93E4-76CF1AD749C3Q34031285-76716676-4DA8-4C69-A9CF-48C3CFB33D33Q34116902-AC2563F4-4670-4E79-ABB1-4BE39CDA2196Q34765294-B9BF4963-EC53-4805-8649-5B16B96040D7Q34926226-75FA7613-6D01-4BBE-881D-165CFA14A98DQ35084020-E43C567B-C96C-4EF4-AD2A-3F0414494FC4Q35625385-4ED8920F-1432-484D-97CC-D3D0C7A4CCD3Q35807959-7CCBAB71-418F-462E-805F-8C27A28E5844Q35817394-33CC675E-0D40-4D55-9B44-4F4E4DF069B1Q35949137-2B409C4C-AFA5-4801-A7B0-63D3A548B27DQ36008171-AAEA26A2-B511-4C55-B073-EAC495FBAA20Q36216230-01B2A3F5-1FB8-4CB0-94E8-8D8136E61CFFQ36507980-033BC78D-9518-4D46-A224-3774204F0386Q36515569-FE5DF65F-AFB5-43B3-9CC5-A1A9BC88A9B8Q36684897-31DC2F97-8FD6-42D7-955C-1385CF0461CEQ36688648-30ED9FBC-9A32-4F28-AF29-4B665BE3D301Q36936451-75F19B1B-5065-4557-A767-03C6E1020F24Q37125395-17BF284B-BCF2-4402-B79F-9F185781006EQ37175356-E0071042-ABC3-43D5-B0F7-B31711532423Q37236903-1F67E0C2-BC7F-40B0-9755-688DA0381C64Q37687407-7BA9B2AC-CA3D-48F8-BF48-6C9ED7226BDCQ37858877-94760219-BA79-4C26-A51E-A9B1393483ADQ38541612-81A7532A-E044-468B-9C2D-CD2F21949AD0Q38769301-4051DB0D-655C-4992-9B8D-AEB5B72AE04DQ38943340-BECCA299-82D5-42F3-90A3-7CF945AD4728Q39057636-C23517CB-BEA5-40D1-85CB-67F83AD9AF3FQ39241897-CE3B53BB-E2E0-447A-9F8B-501BCD0C6FEFQ39361900-09705481-894E-4480-9E03-7ACB5B3F2040Q39391689-21D344B5-4F46-4B55-998A-F44F90C3F687Q39391698-03F16622-4E46-4922-808A-07B551B7F26FQ39726060-7341DC38-BA28-47C0-B100-E6B8BD437A73Q40075629-4479C53D-DD88-414D-8ED6-9A24371EE624Q40140077-62718BD1-EB28-49BB-B230-B45FCAFFE448Q40303741-40560E07-ACDA-431C-B6AE-5D9E9065CA37Q40397695-304EBA75-DB47-4782-BADB-6DD62183BEB2Q40413132-8B6106E6-5129-4712-819C-5FFE31A6B4ACQ40723774-9767F8CC-7152-4CD5-B4FC-511785314E7FQ40785996-878FD7FB-D4EA-449F-9F81-D83491D79FF9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ken I. Mills
@ast
Ken I. Mills
@en
Ken I. Mills
@es
Ken I. Mills
@sl
type
label
Ken I. Mills
@ast
Ken I. Mills
@en
Ken I. Mills
@es
Ken I. Mills
@sl
prefLabel
Ken I. Mills
@ast
Ken I. Mills
@en
Ken I. Mills
@es
Ken I. Mills
@sl
P1053
A-8556-2012
P106
P1153
7202875381
P21
P31
P3829
P496
0000-0002-6362-4481